| 生物活性 |
Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway and suppresses osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication, and cancer cell proliferation, reduces pro-inflammatory cytokine levels, induces cancer cell apoptosis (apoptosis), and exhibits antifungal, antimalarial, antibacterial, and anticonvulsant activities, and it can be used in research on osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload diseases, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria, and bacterial infections. |
体外研究 (In Vitro) |
Rubiadin (5-20 μM;预孵育 3 h,随后继续孵育 24 h) 可保护 N2a 细胞免受 Aβ1₋42 诱导的细胞毒性,与仅经 Aβ1₋42 处理的细胞相比,能显著提高细胞活力。 Rubiadin (5-20 μM;预孵育 3 h,随后继续孵育 24 h) 通过降低关键通路组分的磷酸化水平,抑制 Aβ1-42 诱导的 N2a 细胞中 IKK/IκB/NF-κB 通路的激活。 Rubiadin (1-100 μM;辐照后 24 h) 可在 MCF-7c3 人乳腺癌细胞中诱导具有光剂量依赖性的细胞毒性,其 LD50 为 0.66 J/cm2;在 100 μM 和 1 J/cm2 的条件下,细胞存活率降低 76%。 Rubiadin (0.4-40 μM;24 h) 不会损害人 HepG2 细胞的活力。 Rubiadin (0.4-40 μM;24 h,呈剂量依赖性) 及 Rubiadin (20 μM;3-24 h,呈时间依赖性) 可在人 HepG2 细胞中以剂量依赖和时间依赖的方式上调 hepcidin mRNA 及蛋白的表达,在 20 μM 处理 24 h 时 mRNA 上调幅度达到最高 5 倍。 Rubiadin (5、10、20、40 μg/ml;作用 72 h) 可呈剂量依赖性抑制 HepG2.2.15 细胞的增殖,其 IC50 为 17 μg/ml,且非毒性浓度 (<8 μg/ml) 的特性支持将其用于抗 HBV 活性实验。 Rubiadin (4、6 μg/ml;24、48、72 h) 可剂量依赖性地降低 HepG2.2.15 细胞的 HBsAg、HBeAg 及 HBcAg 分泌水平,且在 72 h 时对 HBeAg 和 HBcAg 的抑制作用尤为显著。 Rubiadin 可抑制热带假丝酵母菌(Candida tropicalis) 生物膜的形成,并在辐照条件下诱导氧化应激,还能与两性霉素 B (Amphotericin B) 协同作用于该真菌。 Rubiadin 可抑制恶性疟原虫 (Plasmodium falciparum) 的活性,其 IC50 为 13.00 μg/mL,并以剂量依赖的方式减少裂殖体数量。 Rubiadin 在水性生理介质 (pH 7.4) 中表现出中等强度的实验性 DPPH 自由基清除活性,其 IC50 为 91.00 μM。 Rubiadin 在生理水性介质 (pH 7.4) 中表现出中等强度的实验性 ABTS•+ 自由基清除活性,其 IC50 为 73.44 μM。
Cell Viability Assay
| Cell Line: |
mouse neuroblastoma N2a cells (Aβ1₋42-induced model) |
| Concentration: |
5 μM; 20 μM |
| Incubation Time: |
3 h pre-incubation, then 24 h continued incubation |
| Result: |
Significantly improved cell viability in Aβ1₋42-exposed N2a cells. |
Western Blot Analysis
| Cell Line: |
mouse neuroblastoma N2a cells (Aβ1₋42-induced model) |
| Concentration: |
5 μM; 20 μM |
| Incubation Time: |
3 h pre-incubation, then 24 h continued incubation |
| Result: |
Reduced the expression levels of pro-inflammatory cytokines IL-1β, IL-6, TNF-α. Increased the expression of anti-inflammatory cytokine IL-4. Decreased phosphorylated Tau protein expression in Aβ1₋42-exposed N2a cells.\nSignificantly inhibited the phosphorylation of IKK, IκB, and NF-κB in Aβ1₋42-exposed N2a cells. |
Immunofluorescence
| Cell Line: |
mouse neuroblastoma N2a cells (Aβ1₋42-induced model) |
| Concentration: |
5 μM; 20 μM |
| Incubation Time: |
3 h pre-incubation, then 24 h continued incubation |
| Result: |
Reversed the increased nuclear overlap of NF-κB and DAPI-labeled nuclei observed in Aβ1₋42-exposed N2a cells. Significantly reduced NF-κB nuclear fluorescence intensity. |
Cell Cytotoxicity Assay
| Cell Line: |
MCF-7c3 human breast cancer cells |
| Concentration: |
1, 50, 100 μM |
| Incubation Time: |
24 h (post-irradiation) |
| Result: |
Exhibited photochemical activity in a light dose-dependent manner, with an LD50 value at 0.66 J/cm2 light dose and 76% cell killing at 1 J/cm2. |
Western Blot Analysis
| Cell Line: |
human HepG2 cells, ferric ammonium citrate (FAC)-treated human HepG2 cells |
| Concentration: |
0.4, 4, 8, 20, 40 μM (untreated cells); 20 μM (FAC-pretreated cells) |
| Incubation Time: |
24 h (untreated cells); 24 h (FAC-pretreated cells) |
| Result: |
Dose-dependently decreased protein expression of TfR1, Fpn1 and FtL in untreated HepG2 cells, with significant reductions at 20 and 40 μM for TfR1 and Fpn1, and at 8, 20, and 40 μM for FtL; had no significant effect on divalen DMT1 or FtH expression.\nFurther decreased TfR1 protein expression and reversed FAC-induced elevation of FtL protein expression in FAC-pretreated HepG2 cells; had no significant effect on Fpn1, DMT1, or FtH expression in FAC-pretreated cells. |
ELISA Assay
| Cell Line: |
HepG2.2.15 human hepatoma cells |
| Concentration: |
4, 6 μg/ml |
| Incubation Time: |
24, 48, 72 h |
| Result: |
Dose-dependently decreased extracellular levels of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antigen (HBcAg). Reduced HBeAg secretion by 26.31% and HBcAg secretion by 29.26% at 72 h, with more efficient inhibition than the positive control. |
Cell Cycle Analysis
| Cell Line: |
HepG2.2.15 human hepatoma cells |
| Concentration: |
4, 6 μg/ml |
| Incubation Time: |
72 h |
| Result: |
Resulted in G0/G1 phase percentages of 75.2% (4 μg/ml) and 78.1% (6 μg/ml), with no statistically significant difference from the untreated control (73.3%). Induced no cell cycle arrest. |
|
体内研究 (In Vivo) |
Rubiadin (0.3-0.5 mg/kg; i.p.; single dose) 具有显著的急性抗炎活性,在雄性 Wistar 白化大鼠中可对角叉菜胶诱导的足爪水肿峰值产生 61%的抑制作用,并显著降低足爪组织中的 TNF-α 水平。 Rubiadin (50-200 mg/kg;灌胃;每日给药;连续 14 天) 对 Sprague-Dawley 大鼠中 CCl4 诱导的肝损伤表现出剂量依赖性的保肝活性,其中 100 和 200 mg/kg 剂量下的疗效具有极显著性,接近阳性对照药物水飞蓟素的活性。 Rubiadin (20 mg/kg; 灌胃给药; 每日 1 次; 连续 8 周) 可改善 APP/PS1 阿尔茨海默病模型小鼠的空间与非空间记忆,减少大脑 Aβ 沉积,缓解神经炎症,并抑制 NF-κB 通路的激活。 Rubiadin (1 mg/kg;腹腔注射;每隔 1 天给药;持续 6 周) 可降低 8 周龄正常雄性 C57BL/6 小鼠的血清铁、总铁结合力及转铁蛋白饱和度。 Rubiadin (5-20 mg/kg; i.p.; 每日;连续 4 周) 可通过逆转脾肿大、降低血清铁参数及十二指肠铁含量、增强肝脏 hepcidin 表达与 SMAD1/5/9 磷酸化,缓解高铁饮食喂养的 C57BL/6 雄性小鼠的铁过载状态。 Rubiadin (100-250 mg/kg;灌胃;每日 1 次;连续 3 天) 对 Swiss albino mice(瑞士白化小鼠) 具有抗惊厥作用,当以 100 和 250 mg/kg 剂量灌胃给药 3 天时,可降低戊四唑模型和最大电休克模型中的癫痫发作严重程度。 Rubiadin (0.04%;膳食性;每日给药;持续 23 周) 是作用于 F344 大鼠的致癌代谢物,当以膳食中 0.04%的剂量给药 23 周时,会促进肾肿瘤前病变、肝细胞灶和肠道发育异常。
| Animal Model: |
Wistar albino rats (male, 150-200 g) |
| Dosage: |
0.3 mg/kg; 0.5 mg/kg |
| Administration: |
i.p.; single dose |
| Result: |
Produced paw edema inhibition percentages of 24% (0.5 hr), 17.5% (1 hr), 8.3% (2 hr), 21% (3 hr), and 13% (4 hr) at 0.3 mg/kg.\nProduced paw edema inhibition percentages of 48% (0.5 hr), 40% (1 hr), 45% (2 hr), 61% (3 hr), and 54% (4 hr) at 0.5 mg/kg, with 61% inhibition at peak edema time being statistically significant.\nCaused a statistically significant decrease in paw tissue TNF-α levels at 0.5 mg/kg compared to controls.\nSignificantly reduced paw tissue edema and histopathological damage compared to controls at both doses. |
| Animal Model: |
Wistar albino rats (male, 150-200 g) |
| Dosage: |
0.3 mg/kg; 0.5 mg/kg |
| Administration: |
i.p.; daily; 7 days |
| Result: |
Produced 34.71% inhibition of granuloma formation and 19.76% inhibition of transudate formation at 0.3 mg/kg.\nProduced 46.12% inhibition of granuloma formation and 38.13% inhibition of transudate formation at 0.5 mg/kg, with both values statistically. Caused a statistically significant decrease in serum IL-1β levels at 0.5 mg/kg compared to controls. |
| Animal Model: |
C57BL/6 (6-week-old, male; high-iron diet-induced iron overload) |
| Dosage: |
5 mg/kg; 20 mg/kg |
| Administration: |
i.p.; daily; 4 weeks |
| Result: |
Did not significantly affect mouse body weight.\nSignificantly reversed splenomegaly, reduced elevated serum iron, total iron-binding capacity, and transferrin saturation caused by the high-iron diet, and reversed the elevated duodenal iron content caused by the high-iron diet.\nFurther increased hepatic hepcidin mRNA expression, hepatic hepcidin protein expression, and hepatic SMAD1/5/9 phosphorylation levels relative to the high-iron diet alone. |
| Animal Model: |
Wistar (carbon tetrachloride-induced liver injury) |
| Dosage: |
50 mg/kg; 100 mg/kg; 200 mg/kg |
| Administration: |
p.o.; daily; 2 weeks |
| Result: |
Restored serum glutamic oxaloacetic transaminase, glutamate pyruvate transaminase, alkaline phosphatase, γ-glutamyltransferase, glutathione S-transferase, and glutathione reductase levels to normal.\nInhibited hepatic malondialdehyde formation in a dose-dependent manner.\nReduced glutathione depletion in a dose-dependent manner. |
| Animal Model: |
Wistar (streptozotocin-nicotinamide-induced diabetic nephropathy) |
| Dosage: |
100 mg/kg/week; 200 mg/kg/week |
| Administration: |
p.o. |
| Result: |
Markedly reduced blood glucose levels, urea, uric acid, and creatinine levels.\nImproved lipid, thiobarbituric acid reactive substances, glutathione, superoxide dismutase, and catalase levels. |
| Animal Model: |
F344 |
| Dosage: |
0.04% |
| Administration: |
dietary; daily; 23 weeks |
| Result: |
Enhanced atypical renal tubules/hyperplasias.\nInduced renal cell adenomas and carcinomas.\nIncreased glutathione S-transferase placental form-positive liver cell foci.\nCaused major intestinal dysplasias. |
|
| 性状 |
固体 |
| 颜色 |
Light yellow to yellow |